Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.

× No keyword cloud information.

11 in total

1. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.

Authors: Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale
Journal: J Allergy Clin Immunol Date: 2003-12 Impact factor: 10.793

2. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.

Authors: Yee Ean Ong; Andrew Menzies-Gow; Julia Barkans; Farid Benyahia; Tsen-Teng Ou; Sun Ying; A Barry Kay
Journal: J Allergy Clin Immunol Date: 2005-09 Impact factor: 10.793

Review 3. Omalizumab for asthma.

Authors: Robert C Strunk; Gordon R Bloomberg
Journal: N Engl J Med Date: 2006-06-22 Impact factor: 91.245

4. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Authors: D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein
Journal: J Immunol Date: 1997-02-01 Impact factor: 5.422

5. No mucosal atrophy and reduced inflammatory cells: active-controlled trial with yearlong fluticasone furoate nasal spray.

Authors: Wytske J Fokkens; Bas Rinia; Cornelis M van Drunen; Peter W Hellings; Greet Hens; Ad Jansen; Henk Blom; Wei Wu; Diane S Clements; Laurie A Lee; Edward E Philpot
Journal: Am J Rhinol Allergy Date: 2012 Jan-Feb Impact factor: 2.467

6. Humanization of an antibody directed against IgE.

Authors: L G Presta; S J Lahr; R L Shields; J P Porter; C M Gorman; B M Fendly; P M Jardieu
Journal: J Immunol Date: 1993-09-01 Impact factor: 5.422

7. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction.

Authors: Sun Ying; Yoko Kikuchi; Qiu Meng; A Barry Kay; Allen P Kaplan
Journal: J Allergy Clin Immunol Date: 2002-04 Impact factor: 10.793

Review 8. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.

Authors: E S Schulman
Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405

Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.

1. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.

2. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.

Review 3. Omalizumab for asthma.

4. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

5. No mucosal atrophy and reduced inflammatory cells: active-controlled trial with yearlong fluticasone furoate nasal spray.

6. Humanization of an antibody directed against IgE.

7. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction.

Review 8. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.

9. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.

10. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.

Review 1. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

2. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.